Gold Investment Management Ltd. Buys 8,943 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Gold Investment Management Ltd. raised its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 12.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,147 shares of the company’s stock after acquiring an additional 8,943 shares during the period. Gold Investment Management Ltd.’s holdings in Takeda Pharmaceutical were worth $1,088,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also bought and sold shares of the company. FMR LLC lifted its position in Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after buying an additional 286,052 shares during the last quarter. Stifel Financial Corp grew its holdings in Takeda Pharmaceutical by 103.9% during the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after acquiring an additional 224,594 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Takeda Pharmaceutical in the 4th quarter valued at $1,447,000. Finally, Verition Fund Management LLC bought a new position in Takeda Pharmaceutical in the third quarter worth about $1,533,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.1 %

NYSE:TAK opened at $15.02 on Monday. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.22. The firm has a 50 day moving average of $13.76 and a 200 day moving average of $13.90. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $47.78 billion, a price-to-earnings ratio of 37.54, a PEG ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.